CAJ | 학술논문

目的观察合并上消化道出血(UGH)高危因素的急性脑梗死患者应用西洛他唑片治疗的有效性和安全性.方法将120例合并UGH高危因素的急性脑梗死患者随机分为两组,阿司匹林组(A组,n=60):口服拜阿司匹林片100 mg,1次/天.西洛他唑组(B组,n=60):口服西洛他唑片100 mg,2次/天.观察随访疗程为6个月,监测治疗前后的血脂指标,记录治疗过程中消化道事件,评估临床疗效.结果 A组与B组临床治疗总有效率比较,差异无统计学意义(88.33％vs.86.67％),P＞0.05;治疗后,B组HDL-C水平显著升高(1.02±0.19vs.1.20±0.18),P＜0.05;B组消化道事件显著低于A组(1例vs.9例),P＜0.01.结论合并UGH高危因素的急性脑梗死患者应用西洛他唑抗血小板治疗是有效和安全的.
목적 관찰합병상소화도출혈(UGH)고위인소적급성뇌경사환자응용서락타서편치료적유효성화안전성.방법 장120례합병UGH고위인소적급성뇌경사환자수궤분위량조,아사필림조(A조,n=60):구복배아사필림편100 mg,1차/천.서락타서조(B조,n=60):구복서락타서편100 mg,2차/천.관찰수방료정위6개월,감측치료전후적혈지지표,기록치료과정중소화도사건,평고림상료효.결과 A조여B조림상치료총유효솔비교,차이무통계학의의(88.33％vs.86.67％),P＞0.05;치료후,B조HDL-C수평현저승고(1.02±0.19vs.1.20±0.18),P＜0.05;B조소화도사건현저저우A조(1례vs.9례),P＜0.01.결론 합병UGH고위인소적급성뇌경사환자응용서락타서항혈소판치료시유효화안전적.
Objective To observe the effect and safety of cilostazol for patients with cerebral infarction combined with upper digestive tract hemorrhage risk factors.Methods 120 patients with acute cerebral infarction and UGH risk factors were randomly divided into an aspirin group (group A,n=60,orally taking aspirin once a day,100 mg once) and a cilostazol group (group B,n=60,orally taking cilostazol twice a day,100 mg once).All patients were observed and followed up for 6 months.The lipid indexes were monitored before and after the treatment,gastrointestinal events during the treatment recorded,and clinical curative effect evaluated.Results There were no statistical difference in clinical efficacy between the two groups (88.33％ vs.86.67％,P ＞ 0.05).After the treatment,the HDL-C level increased more significantly in group B than in group A [(1.02 ± 0.19) vs.(1.20 ± 0.18),P ＜ 0.05].Fewer patients occurred gastrointestinal events in group B than in group A (1 case vs.9 cases,P ＜ 0.05).Conclusions Cilostazol for patients with acute cerebral infarction associated and UGH risk factors is effective and safe.